ZA94446B - Use of monoclonal anti-lfa-1 antibodies for the prepartion of a drug to prevent the rejection of solid organ transplants and drugs obtained - Google Patents

Use of monoclonal anti-lfa-1 antibodies for the prepartion of a drug to prevent the rejection of solid organ transplants and drugs obtained

Info

Publication number
ZA94446B
ZA94446B ZA94446A ZA94446A ZA94446B ZA 94446 B ZA94446 B ZA 94446B ZA 94446 A ZA94446 A ZA 94446A ZA 94446 A ZA94446 A ZA 94446A ZA 94446 B ZA94446 B ZA 94446B
Authority
ZA
South Africa
Prior art keywords
lfa
prepartion
rejection
antibodies
drug
Prior art date
Application number
ZA94446A
Other languages
English (en)
Inventor
Gilles Alberici
Brigitte Le Mauff
Jean-Paul Soulillou
Pierre Caudrelier
Maryvonne Hourmant
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9443248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA94446(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of ZA94446B publication Critical patent/ZA94446B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA94446A 1993-01-21 1994-01-21 Use of monoclonal anti-lfa-1 antibodies for the prepartion of a drug to prevent the rejection of solid organ transplants and drugs obtained ZA94446B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300584A FR2700471B1 (fr) 1993-01-21 1993-01-21 Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.

Publications (1)

Publication Number Publication Date
ZA94446B true ZA94446B (en) 1994-09-01

Family

ID=9443248

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94446A ZA94446B (en) 1993-01-21 1994-01-21 Use of monoclonal anti-lfa-1 antibodies for the prepartion of a drug to prevent the rejection of solid organ transplants and drugs obtained

Country Status (11)

Country Link
US (1) US6214342B1 (de)
EP (1) EP0680336B1 (de)
JP (1) JPH08505638A (de)
AT (1) ATE194497T1 (de)
AU (1) AU677374B2 (de)
CA (1) CA2154278A1 (de)
DE (1) DE69425246T2 (de)
FR (1) FR2700471B1 (de)
NZ (1) NZ259901A (de)
WO (1) WO1994016728A1 (de)
ZA (1) ZA94446B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2763072B1 (fr) * 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
US6222832B1 (en) 1998-06-01 2001-04-24 Tantivy Communications, Inc. Fast Acquisition of traffic channels for a highly variable data rate reverse link of a CDMA wireless communication system
US7936728B2 (en) 1997-12-17 2011-05-03 Tantivy Communications, Inc. System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system
US8175120B2 (en) 2000-02-07 2012-05-08 Ipr Licensing, Inc. Minimal maintenance link to support synchronization
US7394791B2 (en) * 1997-12-17 2008-07-01 Interdigital Technology Corporation Multi-detection of heartbeat to reduce error probability
US9525923B2 (en) 1997-12-17 2016-12-20 Intel Corporation Multi-detection of heartbeat to reduce error probability
US7496072B2 (en) * 1997-12-17 2009-02-24 Interdigital Technology Corporation System and method for controlling signal strength over a reverse link of a CDMA wireless communication system
US8134980B2 (en) 1998-06-01 2012-03-13 Ipr Licensing, Inc. Transmittal of heartbeat signal at a lower level than heartbeat request
US7221664B2 (en) * 1998-06-01 2007-05-22 Interdigital Technology Corporation Transmittal of heartbeat signal at a lower level than heartbeat request
US7773566B2 (en) 1998-06-01 2010-08-10 Tantivy Communications, Inc. System and method for maintaining timing of synchronization messages over a reverse link of a CDMA wireless communication system
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6965778B1 (en) * 1999-04-08 2005-11-15 Ipr Licensing, Inc. Maintenance of channel usage in a wireless communication system
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US8155096B1 (en) 2000-12-01 2012-04-10 Ipr Licensing Inc. Antenna control system and method
US6954448B2 (en) 2001-02-01 2005-10-11 Ipr Licensing, Inc. Alternate channel for carrying selected message types
US7551663B1 (en) 2001-02-01 2009-06-23 Ipr Licensing, Inc. Use of correlation combination to achieve channel detection
CA2867406C (en) 2001-06-13 2016-08-02 Apple Inc. Transmittal of heartbeat signal at a lower level than heartbeat request
US20050266001A1 (en) * 2004-04-02 2005-12-01 Hadley Gregg A Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
EP1735000A2 (de) * 2004-04-16 2006-12-27 Genentech, Inc. Verfahren zur verstärkung des b-zellabbaus
JP6613412B2 (ja) * 2014-04-03 2019-12-04 学校法人獨協学園獨協医科大学 移植免疫応答の抑制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762933A (en) * 1987-01-05 1998-06-09 Institut National De La Sante Et De La Recherche Medicale Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
JP3213314B2 (ja) * 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder

Also Published As

Publication number Publication date
NZ259901A (en) 1997-03-24
WO1994016728A1 (fr) 1994-08-04
FR2700471B1 (fr) 1995-04-07
AU677374B2 (en) 1997-04-24
DE69425246D1 (de) 2000-08-17
FR2700471A1 (fr) 1994-07-22
EP0680336A1 (de) 1995-11-08
AU5887694A (en) 1994-08-15
JPH08505638A (ja) 1996-06-18
DE69425246T2 (de) 2001-01-04
EP0680336B1 (de) 2000-07-12
CA2154278A1 (fr) 1994-08-04
ATE194497T1 (de) 2000-07-15
US6214342B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
AU677374B2 (en) Monoclonal anti-LFA-1 antibodies for the preparation of a medicament intended to prevent the rejection of organ transplants
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
DE3280408T2 (de) Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
CA2163989A1 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
MD1374F2 (en) Monoclonal immunostimulating antibodies, method of obtaining thereof, cell lines, method of disease treatment and pharmaceutical composition
DE3812605A1 (de) Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
DE69812727D1 (de) Opioid-konjugate mit endogenen Trägerproteinen
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ATE433998T1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
IL131655A0 (en) Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs
US7147849B2 (en) Pharmaceutical formulation
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
AU9363398A (en) Hepatitis c receptor protein cd81
NO922621L (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
PT948319E (pt) Celulas encapsuladas produtoras de anticorpos
WO1996032137A3 (en) Methods of inducing immune tolerance using immunotoxins
ATE104860T1 (de) Aktiver wirkstoff und diesen enthaltendes arzneimittel zur verhinderung oder bekaempfung der abstossung von organtransplantaten.
Turk Mucocutaneous Candidiasis: Evidence for a preferential effect of cyclophosphamide on B-cells
Stephanian et al. Prolongation of canine islet allograft survival by 15-deoxyspergualin
Shohat et al. Immunosuppressive activity and polyamine levels of seminal plasma in azo-ospermic, oligospermic, and normospermic men
NZ318272A (en) Glucocorticoid enhancement of gene expression
Nemoto et al. Suppression of experimental allergic encephalomyelitis in guinea pigs by spergualin and 15-deoxyspergualin